Agios Makes Strong Debut in Upsized IPO
Continuing the trend of biotech's upsized initial public offerings (IPOs), Agios Pharmaceuticals Inc. bumped up both the number of shares offered and priced $2 above its proposed range for gross proceeds topping $106 million.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter